Japanese cedar pollinosis
Conditions
Interventions
Pranlukast Hydrate capsules are orally administered to 15 subjects at twice daily one month from Feb. 29 through Feb. 01. Japanese cedar pollen exposure mid-Feb. in OHIO Chamber.
Placebo capsules ar
Sponsors
Nippon Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) CAP-RAST score against Japanese cedar pollen over class 2 in the past. 2) Have experience with cedar pollen exposure in the OHIO Chamber in the past, patients with nasal symptoms with nasal congestion. 3) Patients who were judged to be suitable for patients enrollment by doctor in screening visit or medical examination results. 4) Written informed consent is required.
Exclusion criteria
Exclusion criteria: 1) Some patients with mucosal lesion of the nose and eyes. 2) Patients who received steroid injections within 6 months. 3) Subjects with deformity of the nose or a polyp. 4) Subjects with systemic diseases (asthma or tuberculosis). 5) Patients with past history of anaphylaxis. 6) Patients who have the hypersensitivity to study drug. 7) Patients who have received immunotherapy. 8) Pregnancy, breast-feeding woman, potencial pregnancy, patients who wish to become pregnant during this study. 9) Patients who were judged to be unsuitable for patients enrollment by doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nasal symptoms score | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) No of sneezing 2) Nasal secretion volume 3) Occurrence time of the first nasal symptom | — |
Countries
Japan
Contacts
Public ContactKiyochika Suematsu
Medical Corporation Shinanokai, Samoncho Clinic Pharmaceutical Dept.,
Outcome results
None listed